Mesothelioma is a rare but aggressive form of cancer with limited treatment options. Norwegian biotech Ultimovacs is addressing the need for new therapies with its universal cancer vaccine UV1. BioStock got in touch with the Director Medical Affairs at Ultimovacs, Espen Basmo Ellingsen, to learn more about the overall burden caused by this disease as well as the phase II trial NIPU evaluating UV1 in combination with standard of care.

Read the full article here